CSL Limited Annual Report 2021/22 29 6 Powered by Innovation What stands CSL in good stead is our quantitative approach to understanding the nature and biology of a disease at a molecular and cellular level, married to a deep understanding of the clinical and commercial aspects of those diseases where we aim to introduce new innovative products. CSL’s philosophy of global collaboration underpins our presence within research precincts around the world. Strong global research networks and collaborations are an integral part of our global R&D business as they provide valuable opportunities for our scientists to interact, discover and innovate with external partners. We continue to identify and expand our network of collaborators, both academic and industry-based, to enrich external innovation and thinking. Expanding our R&D footprint CSL continues to advance its global programs and teams and expand its R&D footprint. CSL has: • 2,000+ R&D employees in nine countries, working in integrated teams; • R&D centres located in leading biomedical locations including: – Melbourne in Australia; – Bern in Switzerland; – Marburg in Germany; – Amsterdam in the Netherlands; and – Cambridge, Holly Springs, Pasadena and King of Prussia in the US. • access to worldwide, leading innovation that leverages both the knowledge from CSL employees as well as from research and medical institutions/alliances proximate to CSL’s R&D centres. The following are some notable examples of our investment in our strategic growth over the last 12 months. • Construction of CSL’s new global headquarters in the Parkville Biomedical Precinct in Melbourne, Australia, is on track for completion in early 2023. The base building structure and facade are complete with internal fit-out in progress. The facility will house around 800 employees, including product development teams from throughout CSL R&D, and include leading-edge laboratories along with space for external collaborators, innovators and start-ups. The facility is just 500m from the Bio21 Institute, where CSL’s early stage research team has been based for over 10 years, and will further enable collaboration with other researchers in this multidisciplinary biomedical precinct. • The new R&D campus, in Marburg, Germany will open its doors in September 2022 and will be the new home for about 500 CSL R&D employees as well as hosting academic partners and collaborators. The R&D campus is almost 40,000 square metres including 7,400 m2 of laboratory space, 10,300 square metres of working space, a state of the art vivarium and 905 m2 of collaborative laboratory space. As one of the homes for our future innovation, innovative sustainability was at the forefront of our mind when we designed the building. It was constructed according to KfW (a German state-owned investment and development bank) eligibility criteria for green financing. The investment is consistent with the Sustainable Development Goals of the United Nations – it contributes to the sustainability targets #7 – Affordable and Clean Energy and #13 – Climate Action. • Our new facility in Waltham, Massachusetts, in the US, will support CSL’s growing R&D portfolio, including the self-amplifying mRNA technology platform, the next generation of mRNA vaccine technology, for seasonal and pandemic influenza vaccines. The custom-built facility consists of approximately 13,000 m2 overall including 5,000 m2 of laboratory space and the ability to house about 300 full-time employees. All ongoing R&D programs currently taking place in Cambridge, Massachusetts will transition to the Waltham facility in the coming months and it will act as a future North American campus for global research collaborations. The new site is expected to be fully operational later in 2022.
RkJQdWJsaXNoZXIy MjE2NDg3